rss
Br J Ophthalmol 2008;92:1040-1045 doi:10.1136/bjo.2008.137562
  • Original Article
    • Clinical science

Endoresection in high posterior choroidal melanomas: long-term outcome

  1. J García-Arumí1,2,
  2. M A Zapata1,
  3. O Balaguer1,
  4. A Fonollosa1,
  5. A Boixadera1,
  6. V Martinez-Castillo1
  1. 1
    Hospital Vall d'Hebron, Barcelona, Spain
  2. 2
    Instituto de Microcirugía Ocular (IMO), Barcelona, Spain
  1. Dr M A Zapata, C/Aureli Campmany 2–10, ESC 3, 1, 2, 08172, Sant Cugat del Valles, Barcelona, Spain; zapatavictori{at}hotmail.com
  • Accepted 10 April 2008

Abstract

Background: Eyes with high posterior choroidal melanomas are frequently enucleated because of the potential complications of radiotherapy. The aim of this study was to evaluate the safety and efficacy of endoresection at long-term follow-up.

Methods: Retrospective, non-randomised, interventional case series. Thirty-eight patients underwent endoresection. For primary procedures, inclusion criteria were tumour thickness ≥8 mm, base <15 mm, tumours not exceeding the equatorial area. Endoresection was also undertaken as the salvage procedure in four patients. Main outcomes measured were metastatic disease, survival, local recurrences, visual acuity, enucleation rate, and surgical complications.

Results: Follow-up time ranged from 23 to 129 months (mean 70.63 months). Preoperative visual acuity ranged from “hand-movements” to 20/20 (mean, 20/60). In primary cases, mean tumour thickness was 10.1 mm and mean base diameter 9.9 mm. At the latest visit, 92.1% patients still retained the eye. Final visual acuity ranged from “no light perception” to 20/30 (mean 20/300). Two patients experienced local recurrence before 3 years of follow-up. Melanoma metastatic disease was found in two patients at 5 years of follow-up. Kaplan–Meier survival analysis for all causes was 88.2% at 5 years. Specific survival was 90.9% at 5 years.

Conclusions: At long-term follow-up, the risk of metastasis or local recurrence, and survival rates were similar to other techniques, although comparisons are difficult because of the unusual presentation of this type of melanoma. Further studies and longer follow-up are needed.

Footnotes

  • See Editorials, p 1013 and 1015

  • Competing interests: None.

  • Ethics approval: Ethics approval was obtained from Comité ético Hospital Vall d'Hebron, Barcelona, Spain.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.